Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi J-D, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Sienna, Italy. Eur Neuropsychopharmacol 1998; 8:55-66
Barnes TR, Curson DA: Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf 1994; 10:464-479
Nayak RK, Doose DR, Nair NP: The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987; 27:144-150
Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R: A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159:554-560
Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T: Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci 1994; 19:254-264
Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J: Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry 1991; 158:658-665
Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L: Depot antipsychotic drugs: place in therapy. Drugs 1994; 47:741-773
Adams CE, Fenton MKP, Quraishi S, David AS: Systematic meta-review of depot antipsychotics for people with schizophrenia. Br J Psychiatry 2001; 179:290-299
Walburn J, Gray R, Gournay K, Quraishi S, David AS: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179:300-307
Cramer JA, Rosenheck R: Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49:196-201
Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:103-108; correction, 159:514
Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first-episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241-247
Markowitz JS, Brown CS, Moore TR: Atypical antipsychotics, part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33:73-85
Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346:16-22
Brown CS, Markowitz JS, Moore TR, Parker NG: Atypical antipsychotics, part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999; 33:210-217
Shen WW: The need for depot atypical antipsychotics in the US (editorial). Psychiatr Serv 1998; 49:727
Sarfati Y, Olivier V, Bouhassira M: New antipsychotics in the treatment of schizophrenia: a European survey. Encephale 1999; 25:658-666
Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31:103-115
Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546
Chouinard G, Ross-Chouinard A, Annable L, Jones B: Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 1980; 7:233
Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G: Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001; 62:855-859